Calyxo, Inc. is a clinical-stage medical device company focused on developing and commercializing innovative solutions for kidney stone disease. The company's lead product, CVac, is designed to prevent the recurrence of kidney stones through a minimally invasive procedure that aims to alter the urinary environment to prevent stone formation.

Calyxo, Inc.

Vertex Ventures HC invests in healthcare visionaries to develop novel therapeutic approaches, focusing on the healthcare industry, including biopharmaceuticals, medical devices, and digital health.

Vertex Ventures HC

Questa Capital is a venture growth equity firm focused on later-stage investing in the healthcare services, healthcare technology, and medical device sectors.

Metric
Company Name	Calyxo, Inc.	Vertex Ventures HC
Symbol
MSH ID	COM:QUESTACAPITAL	COM:VERTEXVENTURESHC
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical Devices	Venture Capital
Country	US	US
Stage
Employee Count	14
Website	questacapital.com	vertexventureshc.com
LinkedIn	questa-capital-management
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:QUESTACAPITAL

Calyxo, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue